Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Sold by Principal Financial Group Inc.

Principal Financial Group Inc. lowered its stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 35.1% during the third quarter, according to its most recent 13F filing with the SEC. The firm owned 238,605 shares of the medical equipment provider’s stock after selling 129,130 shares during the quarter. Principal Financial Group Inc. owned 0.34% of Lantheus worth $26,187,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Wilmington Savings Fund Society FSB acquired a new stake in shares of Lantheus in the third quarter valued at about $25,000. Signaturefd LLC lifted its stake in Lantheus by 40.5% in the 3rd quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after buying an additional 92 shares in the last quarter. Nkcfo LLC acquired a new stake in Lantheus in the 2nd quarter worth about $47,000. UMB Bank n.a. increased its stake in Lantheus by 42.1% during the 3rd quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. acquired a new position in shares of Lantheus during the third quarter valued at approximately $51,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on LNTH shares. Redburn Atlantic assumed coverage on Lantheus in a research note on Tuesday, September 3rd. They issued a “buy” rating and a $175.00 price target on the stock. JMP Securities lowered their target price on shares of Lantheus from $125.00 to $112.00 and set a “market outperform” rating on the stock in a research note on Thursday, November 7th. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. The Goldman Sachs Group assumed coverage on shares of Lantheus in a research report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. Finally, Truist Financial reiterated a “buy” rating and issued a $120.00 price objective (down previously from $135.00) on shares of Lantheus in a report on Friday, November 8th. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $131.86.

Lantheus Price Performance

NASDAQ:LNTH opened at $91.30 on Wednesday. The company’s 50-day moving average is $95.36 and its two-hundred day moving average is $98.60. Lantheus Holdings, Inc. has a 1-year low of $50.20 and a 1-year high of $126.89. The firm has a market capitalization of $6.35 billion, a price-to-earnings ratio of 15.19 and a beta of 0.45.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.